US FDA approves GSK's twice-yearly asthma drug

The U.S. Food and Drug Administration has approved GSK's add-on drug to treat asthma and a chronic inflammatory sinus condition, the drugmaker said on Tuesday, paving the way for a less frequently dosed treatment option for patients to enter the market. ...